IOM On “Omics” Assays: Stricter Controls Are Needed For Development Process
This article was originally published in The Gray Sheet
The Institute of Medicine recommends a highly controlled, step-wise approach to bringing complex genomic, proteomic and similar assays from basic research to clinical testing. FDA needs to play a central role, IOM stresses in a recent report.
You may also be interested in...
Although FDA is still developing its lab-developed test regulatory framework, it has agreed not to collect user fees to support its planned review of the tests.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.